Actor portrayals
Moderate to Severe Dyspareunia due to Menopause is Prevalent1
In the EMPOWER survey* of 1858 women suffering from vulvar and vaginal atrophy (VVA), more than half (55%) of women with dyspareunia (n=1093) rated the severity of their pain as moderate to severe1
- Industry-sponsored survey with women aged 45 to 90 years (84% menopausal, 9% perimenopausal; 7% non-menopausal) with at least one VVA symptom, including dyspareunia.1
…and progressive2
VVA symptoms, like moderate to severe dyspareunia, can progress without treatment2
See More
Indication
INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Important Safety Information
INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.
Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.
In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥2 percent were vaginal discharge and abnormal Pap smear.
To report SUSPECTED ADVERSE REACTIONS, contact Millicent Pharma at 1-877-810-2101 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
References: 1. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14:413-424. 2. Wysocki S, Kingsberg A, Krychman M. Management of vaginal atrophy: implications from the REVIVE Survey. Clin Med Insights Reprod Health. 2014;8:23-30.
